Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Representative image: GSK to acquire RAPT Therapeutics for $2.2 billion, strengthening its immunology pipeline with ozureprubart, a long-acting anti-IgE therapy in development for food allergy protection. The asset could shift standard care by enabling quarterly dosing.
Pharma & Biotech

Can GSK’s $2.2bn acquisition of RAPT Therapeutics reshape the food allergy treatment landscape with ozureprubart?

GSK plc has signed a definitive agreement to acquire RAPT Therapeutics Inc., a clinical-stage biopharmaceutical company based in California, in a transaction valued at approximately $2.2 billion. The centerpiece of the deal is ozureprubart, a long-acting anti-IgE monoclonal antibody currently undergoing Phase IIb evaluation for the prophylactic treatment of food allergies. With topline data from

Read More
Pharma & Biotech

Naturmega’s Ruby-O shows bioavailability edge over standard fish oil in peer-reviewed trial

Naturmega’s Ruby-O Balance showed better triglyceride response at a lower dose than fish oil. Find out what this means for the future of omega-3 delivery.

Read More
Pharma & Biotech

Can ketamine treatment clinics like Serenity redefine psychiatric care delivery in suburban America?

Serenity expands ketamine therapy in Florida. Find out how this signals a shift in psychiatric care access and what clinicians are watching next.

Read More
Pharma & Biotech

Is ENHERTU plus pertuzumab on track to redefine first-line treatment in HER2-positive metastatic breast cancer?

EMA begins review of ENHERTU plus pertuzumab for first-line HER2-positive metastatic breast cancer. Find out what this means for frontline therapy options.

Read More
Pharma & Biotech

Akeso’s gumokimab advances to NMPA review in ankylosing spondylitis: Is China’s IL-17 race entering a new phase?

Akeso’s gumokimab enters NMPA review for ankylosing spondylitis after Phase 3 success. Find out what this could mean for IL-17 therapies in China.

Read More
Pharma & Biotech

iRegene’s NouvNeu001 becomes first iPSC therapy with RMAT and Fast Track designations

Find out how iRegene’s iPSC-based Parkinson’s therapy NouvNeu001 became the first to earn both RMAT and Fast Track status from the FDA.

Read More
Pharma & Biotech

How AbbVie’s epcoritamab reshapes the competitive calculus in relapsed diffuse large B-cell lymphoma

AbbVie’s Phase 3 epcoritamab data raise critical questions about survival endpoints and bispecific antibodies in relapsed lymphoma. Read the full analysis.

Read More
Pharma & Biotech

Harbour BioMed converts SPR202 partnership into strategic stake in Spruce Biosciences

Harbour BioMed acquires stake in Spruce Biosciences, reinforcing its SPR202 collaboration. Find out what this signals for CRH-targeted therapies.

Read More
Pharma & Biotech

What AstraZeneca’s C-CAR031 deal reveals about the future of CAR-T in liver cancer

AstraZeneca takes full control of a GPC3 CAR-T therapy for liver cancer. Find out what this deal changes and what risks still loom.

Read More
Pharma & Biotech

What D3 Bio’s dual KRAS IND clearances reveal about the next wave of targeted oncology

D3 Bio secures U.S. FDA IND clearances for two KRAS programs, advancing G12D monotherapy and G12C resistance combo trials. See what this means for oncology.

Read More